RedHill Biopharma Ltd.
RDHL
$1.02
-$0.01-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -49.29% | 15.99% | 157.62% | 108.60% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.29% | 15.99% | 157.62% | 108.60% | -- |
| Cost of Revenue | -30.07% | -30.07% | 29.96% | 18.29% | -- |
| Gross Profit | -17.86% | -17.86% | 255.02% | 125.88% | -- |
| SG&A Expenses | 20.44% | 78.20% | 145.50% | 918.44% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.61% | -130.32% | -9.97% | 3.07% | -- |
| Operating Income | 32.39% | 83.55% | 66.45% | 39.61% | -- |
| Income Before Tax | -1,248.06% | 103.09% | 99.06% | 99.77% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,248.06% | 103.09% | 99.06% | 99.77% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.01% | 65.02% | 69.14% | 68.46% | -- |
| EBIT | 32.39% | 83.55% | 66.45% | 39.61% | -- |
| EBITDA | 33.98% | 74.70% | 53.73% | 12.87% | -- |
| EPS Basic | 31.68% | 93.67% | 94.64% | 94.14% | -- |
| Normalized Basic EPS | -884.13% | -87.53% | 103.47% | 100.27% | -- |
| EPS Diluted | 31.68% | 93.67% | 94.64% | 94.14% | -- |
| Normalized Diluted EPS | -884.13% | -87.53% | 103.47% | 100.27% | -- |
| Average Basic Shares Outstanding | 41.01% | 26.50% | 101.62% | 177.71% | -- |
| Average Diluted Shares Outstanding | 50.00% | 33.33% | 100.00% | 300.00% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |